Evidence map›Paper›PMID 39755661›Full record

ArticleMicrobial cell factories2025

Evaluation of the antibacterial and antibiofilm effect of mycosynthesized silver and selenium nanoparticles and their synergistic effect with antibiotics on nosocomial bacteria.

Nahed Fathallah Fahmy, Marwa Mahmoud Abdel-Kareem, Heba A Ahmed, Mena Zarif Helmy, Ekram Abdel-Rahman Mahmoud

Abstract read
In one paragraph

Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Bacterial responses toRSC advances · 2025
    Article
  15. Biosynthesis and Characterization of Selenium Nanoparticles byIranian journal of pharmaceutical research : IJPR
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nahed Fathallah FahmyMicrobiology and Immunology Department, Faculty of Medicine, Sohag University, Sohag, Egypt.
Marwa Mahmoud Abdel-KareemBotany and Microbiology Department, Faculty of Science, Sohag University, Sohag, 82524, Egypt. marwa_abdelkareem@science.sohag.edu.eg.
Heba A AhmedClinical and Chemical Pathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt.
Mena Zarif HelmyGeneral Laparoscopic and Oncology Surgical Department, Sohag University Hospital, Sohag, Egypt.
Ekram Abdel-Rahman MahmoudMicrobiology and Immunology Department, Faculty of Medicine, Sohag University, Sohag, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe healthcare sector faces a growing threat from the rise of highly resistant microorganisms, particularly Methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa). Facing the challenge of antibiotic resistance, nanoparticles have surfaced as promising substitutes for antimicrobial therapy. Recent studies showcase the effectiveness of various fungi species in nanoparticle synthesis. Mycosynthesized silver nanoparticles (AgNPs) and selenium nanoparticles (SeNPs) using Aspergillus carneus MAK 259 has been investigated and demonstrate antibacterial, antibiofilm and synergistic activities against (MRSA) and (MDR P. aeruginosa).

resultsIn the current research, silver nanoparticles (AgNPs) and selenium nanoparticles (SeNPs) were produced extracellularly using A. carneus MAK 259 culture supernatants. Colour change, an initial evaluation of the production of AgNPs and SeNPs. Then, UV absorption peaks at 410 nm and 260 nm confirmed the production of AgNPs and SeNPs, respectively. AgNPs and SeNPs were dispersed consistently between 5‒26 nm and 20-77 nm in size, respectively using TEM. FT-IR analysis was used for assessing proteins bound to the produced nanoparticles. The crystallinity and stability of AgNPs and SeNPs was confirmed using X-ray diffraction analysis and zeta potential measurements, respectively. Antibacterial, antibiofilm and synergistic effects of both (NPs) with antibiotics against MRSA and MDR P. aeruginosa were tested by Agar well diffusion, tissue culture plate and disc diffusion method respectively. Both (NPs) inhibited the growth of P. aeruginosa more than S. aureus. But, SeNPs was stronger. AgNPs had stronger antibiofilm effect especially on biofilms producing S. aureus. as regard synergestic effects, Both (NPs) had higher synergestic effects in combination with cell wall inhibiting antibiotics against P. aeuroginosa While, on S. aureus with antibiotics that inhibit protein synthesis and affect metabolic pathways.

conclusionsOur study demonstrated that the mycosynthesized SeNPs had remarkable antibacterial effect while, mycosynthesized AgNPs exhibited a considerable antibiofilm effect. Both NPs exhibited higher synergistic effect with antibiotics with different modes of action. This approach could potentially enhance the efficacy of existing antibiotics, providing a new weapon against drug-resistant bacteria where the described silver and selenium nanoparticles play a pivotal role in revolutionizing healthcare practices, offering innovative solutions to combat antibiotic resistance, and contributing to the development of advanced medical technologies.

Indexed as

Anti-Bacterial AgentsBiofilmsDrug SynergismMetal NanoparticlesMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsPseudomonas aeruginosaSeleniumSilverAspergillusDrug Resistance, Multiple, BacterialHumansAnti-Bacterial AgentsSeleniumSilverAntibacterialAntibiofilmAspergillus carneusCharacterizationSilver and selenium nanoparticlesSynergistic effect

Identifiers

PMID39755661
PMCPMC11700447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.